98%
921
2 minutes
20
Background: Following transcatheter aortic valve implantation (TAVI), transvalvular mean gradient is known to increase from immediate to 24 h post-procedure. While anesthesia, rapid-pacing, and volume status are blamed, the true etiology is unclear. To our knowledge, no prior studies have evaluated the effects of mitral regurgitation (MR) on the rise in post-TAVI transvalvular mean gradient.
Methods: A single-center, retrospective analysis of patients who underwent TAVI at our institution between 2011 to 2020 was performed (n = 378, males = 206). Patients were divided into two groups, no-to-mild MR (n = 327) and moderate-to-severe MR (n = 51) based on echocardiograms obtained prior to TAVI. Transvalvular gradients were compared between immediate and 24-h post-TAVI echocardiograms.
Results: The average age of no-to-mild MR patients (77 years (interquartile range (IQR): 71 - 84)) was similar to moderate-to-severe MR patients (79 years (IQR: 76 - 85), p=0.13). Both groups had similar procedural blood pressures and peri-procedural medication use. The change in 24-h post-TAVI mean transvalvular gradient was +6 mm Hg (IQR: 3.7 - 9) in the moderate-to-severe MR group and +6 mm Hg (IQR: 3.4 - 9) in the no-to-mild MR group (P = 0.87).
Conclusions: In this study, we evaluated the impact of preexisting MR on changes in transvalvular gradients following TAVI. We observed no statistically significant difference in 24-h post-TAVI gradient changes between patients with moderate-to-severe MR and those with no-to-mild MR. These findings suggest that baseline MR may not be a major determinant of early post-TAVI hemodynamics; however, further prospective studies are needed to confirm this observation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339264 | PMC |
http://dx.doi.org/10.14740/cr2086 | DOI Listing |
Circ Cardiovasc Interv
September 2025
Keele Cardiovascular Research Group, Keele University, United Kingdom (M.A.M., R.B.).
Background: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR).
Methods: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR.
Cardiol Young
September 2025
Congenital Valve Procedural Planning Program, Division of Pediatric Cardiac Surgery, Cleveland Clinic Children's, and Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
Background: Congenital aortic valvar disease represents a heterogeneous population with suboptimal surgical repair or replacement outcomes. We assess our approach and short-term outcomes in this population using cardiac CT evaluation for personalised surgical planning and execution.
Methods: We assessed patients who underwent aortic valvar surgery from February 2022 to August 2024.
Catheter Cardiovasc Interv
September 2025
Department of Cardiology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Background: Asymmetric underexpansion of transcatheter heart valves (THVs), as observed on fluoroscopy, may influence prosthesis function or long-term durability of transcatheter aortic valve implantation (TAVI).
Aims: This study aimed to evaluate the effect of stent frame asymmetry on hemodynamic performance and clinical outcomes in ACURATE neo and neo2 THVs.
Methods: In a retrospective registry, the TAVI asymmetry index was defined as the ratio of the THV stent frame diameter.
J Pediatr Surg
September 2025
University of Utah, Department of Surgery, Division of Pediatric Surgery. Electronic address:
Background: Routine preoperative echocardiograms (ECHOs) are frequently obtained in patients undergoing minimally invasive repair of pectus excavatum (MIRPE), but the benefit and necessity of preoperative screening remain debated. In this study, we sought to quantify the proportion of preoperative ECHOs that had clinically significant findings.
Methods: We conducted a retrospective review of 255 patients who underwent MIRPE at a single pediatric referral center from 2018 to 2023.
J Thorac Cardiovasc Surg
September 2025
Population Health Research Institute, Hamilton Health Sciences, McMaster University, Ontario, Canada.
Objective: Societal guidelines recommend vitamin K antagonists (VKAs) for atrial fibrillation patients with recent biological valve implantation, but the safety and efficacy of direct oral anticoagulants (DOACs) in this setting remain uncertain, especially in the early postoperative period. This substudy of the Left Atrial Appendage Occlusion Study (LAAOS) III trial aimed to compare thromboembolic and bleeding outcomes in patients discharged on VKAs versus DOACs after bioprosthesis implantation or mitral valve repair.
Methods: A total of 2,645 patients were included, with 461 discharged on DOACs and 2184 on VKAs.